<DOC>
	<DOC>NCT01237873</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and tolerability of the combination of aliskiren and amlodipine given to patients with essential hypertension. This study is being conducted to support registration of the fixed combination of aliskiren/amlodipine in the treatment for hypertension in Japan.</brief_summary>
	<brief_title>Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients that complete CSPA100A1301 study Patients whose blood pressure at Visit 7 of CSPA100A1301 study must be well controlled Patients who experienced any serious adverse events considered drug related in CSPA100A1301 study Presence of major protocol violation in CSPA100A1301 study Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Essential hypertension</keyword>
	<keyword>Long term</keyword>
</DOC>